{
  "found": true,
  "heading": "References",
  "content": "1. Pirracchio R, Venkatesh B, Legrand M (2024) Low dose corticosteroids for critically ill adults with severe pulmonary infections: a review. JAMA. https:// doi. org/ 10. 1001/ jama. 2024. 6096\n2. Torres A, Sibila O, Ferrer M et al (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313:677. https:// doi. org/ 10. 1001/ jama. 2015. 88\n3. Taenaka H, Wick KD, Sarma A et al (2024) Biological effects of corticoster oids on pneumococcal pneumonia in mice—translational significance. Crit Care 28:185. https:// doi. org/ 10. 1186/ s13054 024 04956 6\n4. Sterne JAC, Murthy S, The WHO Rapid Evidence Appraisal for COVID 19 Therapies (REACT) Working Group et al (2020) Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID 19: a meta analysis. JAMA. 324:1330. https:// doi. org/ 10. 1001/ jama. 2020. 17023\n5. Dequin P F, Meziani F, Quenot J P et al (2023) Hydrocortisone in severe community acquired pneumonia. N Engl J Med 388:1931 1941. https:// doi. org/ 10. 1056/ NEJMo a2215 145\n6. Heming N, Renault A, Kuperminc E et al (2024) Hydrocortisone plus fludrocortisone for community acquired pneumonia related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial. Lancet Respir Med 12:366 374. https:// doi. org/ 10. 1016/ S2213 2600(23) 00430 7\n7. Chaudhuri D, Nei AM, Rochwerg B et al (2024) Focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community acquired pneumonia. Crit Care Med 52:e219 e233. https:// doi. org/ 10. 1097/ CCM. 00000 00000 006172\n8. Liu J, Dong Y, Chen J et al (2024) Corticosteroid in non COVID 19 induced community acquired pneumonia, a meta analysis. Heart Lung 65:59 71. https:// doi. org/ 10. 1016/j. hrtlng. 2024. 02. 004\n9. Meduri GU, Shih M C, Bridges L et al (2022) Low dose methylpredniso lone treatment in critically ill patients with severe community acquired\npneumonia. Intensive Care Med 48:1009 1023. https:// doi. org/ 10. 1007/ s00134 022 06684 3\n10. Pitre T, Abdali D, Chaudhuri D et al (2023) Corticosteroids in community acquired bacterial pneumonia: a systematic review, pairwise and dose response meta analysis. J Gen Intern Med 38:2593 2606. https:// doi. org/ 10. 1007/ s11606 023 08203 6\n11. Bergmann F, Pracher L, Sawodny R et al (2023) Efficacy and safety of cor ticosteroid therapy for community acquired pneumonia: a meta analysis and meta regression of randomized, controlled trials. Clin Infect Dis 77:1704 1713. https:// doi. org/ 10. 1093/ cid/ ciad4 96\n12. Cheema HA, Musheer A, Ejaz A et al (2024) Efficacy and safety of corticosteroids for the treatment of community acquired pneumonia: a systematic review and meta analysis of randomized controlled trials. J Crit Care 80:154507. https:// doi. org/ 10. 1016/j. jcrc. 2023. 154507\n13. See XY, Wang TH, Chang Y C et al (2024) Impact of different corticoster oids on severe community acquired pneumonia: a systematic review and meta analysis. BMJ Open Respir Res 11:e002141. https:// doi. org/ 10. 1136/ bmjre sp 2023 002141\n14. Bradbury CA, Lawler PR, McVerry BJ et al (2023) Continuation of thera peutic dose heparin for critically ill patients with COVID 19. Intensive Care Med 49:873 875. https:// doi. org/ 10. 1007/ s00134 023 07095 8\n15. Florescu S, Stanciu D, Writing Committee for the REMAP CAP Investiga tors et al (2023) Effect of angiotensin converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support free days in patients hospitalized with COVID 19: a randomized clinical trial. JAMA 329:1183. https:// doi. org/ 10. 1001/ jama. 2023. 4480\n16. Florescu S, Stanciu D, REMAP CAP Writing Committee for the REMAP CAP Investigators et al (2022) Effect of antiplatelet therapy on survival and organ support free days in critically ill patients with COVID 19: a rand omized clinical trial. JAMA 327:1247. https:// doi. org/ 10. 1001/ jama. 2022. 2910\n17. Abdelhady H, Abdelrazik M, Writing Committee for the REMAP CAP Inves tigators et al (2021) Effect of convalescent plasma on organ support free days in critically ill patients with COVID 19: a randomized clinical trial. JAMA 326:1690. https:// doi. org/ 10. 1001/ jama. 2021. 18178\n18. Angus DC, Derde L, The Writing Committee for the REMAP CAP Investiga tors et al (2020) Effect of hydrocortisone on mortality and organ support in patients with severe COVID 19: the REMAP CAP COVID 19 corticoster oid domain randomized clinical trial. JAMA 324:1317. https:// doi. org/ 10. 1001/ jama. 2020. 17022\n19. The REMAP CAP Investigators (2021) Interleukin 6 receptor antagonists in critically ill patients with Covid 19. N Engl J Med 384:1491 1502. https:// doi. org/ 10. 1056/ NEJMo a2100 433\n20. Florescu S, Stanciu D, Writing Committee for the REMAP CAP Investiga tors et al (2023) Long term (180 Day) outcomes in critically ill patients with COVID 19 in the REMAP CAP randomized clinical trial. JAMA 329:39. https:// doi. org/ 10. 1001/ jama. 2022. 23257\n21. Arabi YM, Gordon AC, Derde LPG et al (2021) Lopinavir ritonavir and hydroxychloroquine for critically ill patients with COVID 19: REMAP CAP randomized controlled trial. Intensive Care Med 47:867 886. https:// doi. org/ 10. 1007/ s00134 021 06448 5\n22. The REMAP CAP, ACTIV 4a, and ATT ACC Investigators (2021) Therapeutic anticoagulation with heparin in critically ill patients with Covid 19. N Engl J Med 385:777 789. https:// doi. org/ 10. 1056/ NEJMo a2103 417\n23. The ATT ACC , ACTIV 4a, and REMAP CAP Investigators (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with Covid 19. N Engl J Med 385:790 802. https:// doi. org/ 10. 1056/ NEJMo a2105 911\n24. Angus DC, Berry S, Lewis RJ et al (2020) The REMAP CAP (randomized embedded multifactorial adaptive platform for community acquired pneumonia) study. rationale and design. Ann Am Thorac Soc 17:879 891. https:// doi. org/ 10. 1513/ Annal sATS. 202003 192SD\n25. Angus DC (2015) Fusing randomized trials with big data: the key to self learning health care systems? JAMA 314:767. https:// doi. org/ 10. 1001/ jama. 2015. 7762\n26. Aliberti S, Dela Cruz CS, Amati F et al (2021) Community acquired pneu monia. The Lancet 398:906 919. https:// doi. org/ 10. 1016/ S0140 6736(21) 00630 9\n27. Hayes BH, Haberling DL, Kennedy JL et al (2018) Burden of pneumonia associated hospitalizations. Chest 153:427 437. https:// doi. org/ 10. 1016/j. chest. 2017. 09. 041\n679\n680\n28. Sumibcay JRC, Kunichoff D, Bassett MT (2024) Racial and ethnic dispari ties in COVID 19 mortality. JAMA Netw Open 7:e2411656. https:// doi. org/ 10. 1001/ jaman etwor kopen. 2024. 11656\n29. Chua WY, Chew N, Iyer SC et al (2024) Corticosteroids in critically ill patients with community acquired pneumonia: a systematic review and Bayesian meta analysis. Ann Acad Med Singapore. 53:683 693. https:// doi. org/ 10. 47102/ annals acadm edsg. 20241 59\n30. Sprung CL, Annane D, Keh D et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111 124. https:// doi. org/ 10. 1056/ NEJMo a0713 66\n31. Venkatesh B, Finfer S, Cohen J et al (2018) Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 378:797 808. https:// doi. org/ 10. 1056/ NEJMo a1705 835\n32. Wittermans E, Van Der Zee PA, Qi H et al (2022) Community acquired pneumonia subgroups and differential response to corticosteroids: a secondary analysis of controlled studies. ERJ Open Res 8:00489 02021. https:// doi. org/ 10. 1183/ 23120 541. 00489 2021",
  "items": [
    "1. Pirracchio R, Venkatesh B, Legrand M (2024) Low dose corticosteroids for critically ill adults with severe pulmonary infections: a review. JAMA. https:// doi. org/ 10. 1001/ jama. 2024. 6096",
    "2. Torres A, Sibila O, Ferrer M et al (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313:677. https:// doi. org/ 10. 1001/ jama. 2015. 88",
    "3. Taenaka H, Wick KD, Sarma A et al (2024) Biological effects of corticoster oids on pneumococcal pneumonia in mice—translational significance. Crit Care 28:185. https:// doi. org/ 10. 1186/ s13054 024 04956 6",
    "4. Sterne JAC, Murthy S, The WHO Rapid Evidence Appraisal for COVID 19 Therapies (REACT) Working Group et al (2020) Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID 19: a meta analysis. JAMA. 324:1330. https:// doi. org/ 10. 1001/ jama. 2020. 17023",
    "5. Dequin P F, Meziani F, Quenot J P et al (2023) Hydrocortisone in severe community acquired pneumonia. N Engl J Med 388:1931 1941. https:// doi. org/ 10. 1056/ NEJMo a2215 145",
    "6. Heming N, Renault A, Kuperminc E et al (2024) Hydrocortisone plus fludrocortisone for community acquired pneumonia related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial. Lancet Respir Med 12:366 374. https:// doi. org/ 10. 1016/ S2213 2600(23) 00430 7",
    "7. Chaudhuri D, Nei AM, Rochwerg B et al (2024) Focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community acquired pneumonia. Crit Care Med 52:e219 e233. https:// doi. org/ 10. 1097/ CCM. 00000 00000 006172",
    "8. Liu J, Dong Y, Chen J et al (2024) Corticosteroid in non COVID 19 induced community acquired pneumonia, a meta analysis. Heart Lung 65:59 71. https:// doi. org/ 10. 1016/j. hrtlng. 2024. 02. 004",
    "9. Meduri GU, Shih M C, Bridges L et al (2022) Low dose methylpredniso lone treatment in critically ill patients with severe community acquired",
    "pneumonia. Intensive Care Med 48:1009 1023. https:// doi. org/ 10. 1007/ s00134 022 06684 3",
    "10. Pitre T, Abdali D, Chaudhuri D et al (2023) Corticosteroids in community acquired bacterial pneumonia: a systematic review, pairwise and dose response meta analysis. J Gen Intern Med 38:2593 2606. https:// doi. org/ 10. 1007/ s11606 023 08203 6",
    "11. Bergmann F, Pracher L, Sawodny R et al (2023) Efficacy and safety of cor ticosteroid therapy for community acquired pneumonia: a meta analysis and meta regression of randomized, controlled trials. Clin Infect Dis 77:1704 1713. https:// doi. org/ 10. 1093/ cid/ ciad4 96",
    "12. Cheema HA, Musheer A, Ejaz A et al (2024) Efficacy and safety of corticosteroids for the treatment of community acquired pneumonia: a systematic review and meta analysis of randomized controlled trials. J Crit Care 80:154507. https:// doi. org/ 10. 1016/j. jcrc. 2023. 154507",
    "13. See XY, Wang TH, Chang Y C et al (2024) Impact of different corticoster oids on severe community acquired pneumonia: a systematic review and meta analysis. BMJ Open Respir Res 11:e002141. https:// doi. org/ 10. 1136/ bmjre sp 2023 002141",
    "14. Bradbury CA, Lawler PR, McVerry BJ et al (2023) Continuation of thera peutic dose heparin for critically ill patients with COVID 19. Intensive Care Med 49:873 875. https:// doi. org/ 10. 1007/ s00134 023 07095 8",
    "15. Florescu S, Stanciu D, Writing Committee for the REMAP CAP Investiga tors et al (2023) Effect of angiotensin converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support free days in patients hospitalized with COVID 19: a randomized clinical trial. JAMA 329:1183. https:// doi. org/ 10. 1001/ jama. 2023. 4480",
    "16. Florescu S, Stanciu D, REMAP CAP Writing Committee for the REMAP CAP Investigators et al (2022) Effect of antiplatelet therapy on survival and organ support free days in critically ill patients with COVID 19: a rand omized clinical trial. JAMA 327:1247. https:// doi. org/ 10. 1001/ jama. 2022. 2910",
    "17. Abdelhady H, Abdelrazik M, Writing Committee for the REMAP CAP Inves tigators et al (2021) Effect of convalescent plasma on organ support free days in critically ill patients with COVID 19: a randomized clinical trial. JAMA 326:1690. https:// doi. org/ 10. 1001/ jama. 2021. 18178",
    "18. Angus DC, Derde L, The Writing Committee for the REMAP CAP Investiga tors et al (2020) Effect of hydrocortisone on mortality and organ support in patients with severe COVID 19: the REMAP CAP COVID 19 corticoster oid domain randomized clinical trial. JAMA 324:1317. https:// doi. org/ 10. 1001/ jama. 2020. 17022",
    "19. The REMAP CAP Investigators (2021) Interleukin 6 receptor antagonists in critically ill patients with Covid 19. N Engl J Med 384:1491 1502. https:// doi. org/ 10. 1056/ NEJMo a2100 433",
    "20. Florescu S, Stanciu D, Writing Committee for the REMAP CAP Investiga tors et al (2023) Long term (180 Day) outcomes in critically ill patients with COVID 19 in the REMAP CAP randomized clinical trial. JAMA 329:39. https:// doi. org/ 10. 1001/ jama. 2022. 23257",
    "21. Arabi YM, Gordon AC, Derde LPG et al (2021) Lopinavir ritonavir and hydroxychloroquine for critically ill patients with COVID 19: REMAP CAP randomized controlled trial. Intensive Care Med 47:867 886. https:// doi. org/ 10. 1007/ s00134 021 06448 5",
    "22. The REMAP CAP, ACTIV 4a, and ATT ACC Investigators (2021) Therapeutic anticoagulation with heparin in critically ill patients with Covid 19. N Engl J Med 385:777 789. https:// doi. org/ 10. 1056/ NEJMo a2103 417",
    "23. The ATT ACC , ACTIV 4a, and REMAP CAP Investigators (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with Covid 19. N Engl J Med 385:790 802. https:// doi. org/ 10. 1056/ NEJMo a2105 911",
    "24. Angus DC, Berry S, Lewis RJ et al (2020) The REMAP CAP (randomized embedded multifactorial adaptive platform for community acquired pneumonia) study. rationale and design. Ann Am Thorac Soc 17:879 891. https:// doi. org/ 10. 1513/ Annal sATS. 202003 192SD",
    "25. Angus DC (2015) Fusing randomized trials with big data: the key to self learning health care systems? JAMA 314:767. https:// doi. org/ 10. 1001/ jama. 2015. 7762",
    "26. Aliberti S, Dela Cruz CS, Amati F et al (2021) Community acquired pneu monia. The Lancet 398:906 919. https:// doi. org/ 10. 1016/ S0140 6736(21) 00630 9",
    "27. Hayes BH, Haberling DL, Kennedy JL et al (2018) Burden of pneumonia associated hospitalizations. Chest 153:427 437. https:// doi. org/ 10. 1016/j. chest. 2017. 09. 041",
    "679",
    "680",
    "28. Sumibcay JRC, Kunichoff D, Bassett MT (2024) Racial and ethnic dispari ties in COVID 19 mortality. JAMA Netw Open 7:e2411656. https:// doi. org/ 10. 1001/ jaman etwor kopen. 2024. 11656",
    "29. Chua WY, Chew N, Iyer SC et al (2024) Corticosteroids in critically ill patients with community acquired pneumonia: a systematic review and Bayesian meta analysis. Ann Acad Med Singapore. 53:683 693. https:// doi. org/ 10. 47102/ annals acadm edsg. 20241 59",
    "30. Sprung CL, Annane D, Keh D et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111 124. https:// doi. org/ 10. 1056/ NEJMo a0713 66",
    "31. Venkatesh B, Finfer S, Cohen J et al (2018) Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 378:797 808. https:// doi. org/ 10. 1056/ NEJMo a1705 835",
    "32. Wittermans E, Van Der Zee PA, Qi H et al (2022) Community acquired pneumonia subgroups and differential response to corticosteroids: a secondary analysis of controlled studies. ERJ Open Res 8:00489 02021. https:// doi. org/ 10. 1183/ 23120 541. 00489 2021"
  ]
}